Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Medicinas Complementárias
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Naunyn Schmiedebergs Arch Pharmacol ; 394(2): 249-259, 2021 02.
Artículo en Inglés | MEDLINE | ID: mdl-32936352

RESUMEN

Cisplatin (CP) is nephrotoxic, and this side effect is used as an animal model for acute kidney injury (AKI). Earlier research has been focused on CP-induced AKI, with relatively little attention being paid to its ability to progress to chronic kidney disease (CKD) on repeated administration. We aimed here to test the dose dependency of its nephrotoxic actions by comparing various physiological, biochemical, molecular, and histopathological indices using repeated increasing doses of CP in rats. Furthermore, we investigated whether these doses of CP would result in the development of CKD. Biochemical, molecular, and histopathological measurements were conducted in plasma, urine, and/or kidneys of rats treated with increasing doses of CP at 1.6, 3.2, and 4.8 mg kg-1 weekly for four consecutive weeks. These doses induced significant and dose-dependent elevations in most of the measured renal indices. These included increased renal fibrosis, as suggested histopathologically and biochemically by the significant increase in transforming growth factor-ß1, significant decrease in actin alpha 2, and variable actions of collagen I and IV. CP also dose-dependently increased nuclear factor (erythroid-derived 2)-like 2 and caspase-3. Multiple repeated doses of CP (1.6 to 4.8 mg kg-1) induced multiple episodes of AKI, leading to CKD after the 4th weekly dose and confirmed that this dosage regimen could be used as an experimental animal model of AKI progressing to CKD. These actions were driven by inflammation, oxidative, and nitrosative stress.


Asunto(s)
Lesión Renal Aguda/inducido químicamente , Antineoplásicos/administración & dosificación , Cisplatino/administración & dosificación , Modelos Animales de Enfermedad , Insuficiencia Renal Crónica/inducido químicamente , Lesión Renal Aguda/complicaciones , Lesión Renal Aguda/metabolismo , Lesión Renal Aguda/patología , Albuminuria/sangre , Albuminuria/inducido químicamente , Albuminuria/patología , Albuminuria/orina , Animales , Antineoplásicos/efectos adversos , Caspasa 3 , Cisplatino/efectos adversos , Creatinina/sangre , Creatinina/metabolismo , Creatinina/orina , Citocinas , Relación Dosis-Respuesta a Droga , Proteínas de Unión a Ácidos Grasos/metabolismo , Indicán/sangre , Riñón/efectos de los fármacos , Riñón/metabolismo , Riñón/patología , Masculino , Factor 2 Relacionado con NF-E2/metabolismo , Fósforo/sangre , Ratas Wistar , Insuficiencia Renal Crónica/etiología , Insuficiencia Renal Crónica/metabolismo , Insuficiencia Renal Crónica/patología , Urea/sangre , Ácido Úrico/sangre
2.
Biomed Pharmacother ; 131: 110761, 2020 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-33152924

RESUMEN

Cisplatin (CP) is a potent anticancer drug used to treat solid tumors. Its use, however, is dose-limited by its nephrotoxicity. We aimed to compare the effect of melatonin and curcumin given singly, with that of a combination of these two agents on CP-induced nephrotoxicity in rats. CP (6 mg/kg, given once intraperitoneally) induced nephrotoxicity as evidenced by several significant adverse physiological, biochemical and histopathological actions that included a reduction in body weight, increased urine production, and significant alterations in some conventional and novel renal damage indices in plasma, urine and kidneys. CP also elevated several pro-inflammatory cytokines and caused renal oxidative/nitrosative stress. Supplementation with either curcumin (200 mg/kg) or melatonin (10 mg /kg) given singly by oral gavage for eight consecutive days prior to CP injection and four days thereafter, significantly mitigated the adverse renal effects of CP, by attenuating the pro-inflammatory and apoptotic mediators and improving antioxidant competence in renal tissues of CP- treated rats. When curcumin and melatonin were given together, the ameliorative effect was augmented in some of the measured indices e.g. tumor necrosis factor alpha, cystatin C, uric acid, phosphorus in plasma and, urine creatinine and creatinine clearance. Renal platinum concertation was reduced more with curcumin than that with melatonin, while the reduction was maximized when both melatonin and curcumin were given. Pending further pharmacological and toxicological studies, a combination of these two agents is likely to be mor effective in mitigating the adverse renal effects of CP administered to cancer patients.


Asunto(s)
Cisplatino/toxicidad , Curcumina/farmacología , Enfermedades Renales/prevención & control , Melatonina/farmacología , Animales , Antineoplásicos/toxicidad , Antioxidantes/metabolismo , Apoptosis/efectos de los fármacos , Curcumina/administración & dosificación , Citocinas/metabolismo , Quimioterapia Combinada , Mediadores de Inflamación/metabolismo , Enfermedades Renales/inducido químicamente , Masculino , Melatonina/administración & dosificación , Estrés Nitrosativo/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Ratas , Ratas Wistar
3.
J Pharm Pharmacol ; 69(9): 1219-1229, 2017 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-28542915

RESUMEN

OBJECTIVES: The aim of this work was to assess the possible beneficial effects of aqueous extracts of Hibiscus sabdariffa L. calyces and anthocyanins isolated therefrom in an adenine-induced chronic kidney disease (CKD) model. METHODS: Rats were orally given, for 28 consecutive days, either adenine alone or together with either aqueous extract of H. sabdariffa calyces (5 and 10%) or anthocyanins (50, 100 and 200 mg/kg of anthocyanin concentrate). For comparative purposes, two groups of rats were given lisinopril (10 mg/kg). KEY FINDINGS: When either H. sabdariffa aqueous extract or the anthocyanins isolated from it was administered along with adenine, the adverse effects of adenine-induced CKD were significantly lessened, mostly in a dose-dependent manner. The positive effects were similar to those obtained by administration of lisinopril. CONCLUSIONS: The results obtained show that both H. sabdariffa and its anthocyanins could be considered as possible promising safe dietary agents that could be used to attenuate the progression of human CKD. This could have added significance as H. sabdariffa tea is widely consumed in many parts of Africa and Asia and is thus readily available.


Asunto(s)
Antocianinas/farmacología , Hibiscus/química , Extractos Vegetales/farmacología , Insuficiencia Renal Crónica/tratamiento farmacológico , Adenina/toxicidad , Administración Oral , Animales , Antocianinas/administración & dosificación , Antocianinas/aislamiento & purificación , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Lisinopril/farmacología , Masculino , Extractos Vegetales/administración & dosificación , Ratas , Ratas Wistar , Insuficiencia Renal Crónica/fisiopatología
4.
Nat Prod Commun ; 12(1): 43-45, 2017 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-30549821

RESUMEN

Extracts of Hibiscus sabdarnffa calyces have been shown to have various medicinal properties, some of which have been reported to be due to anthocyanins present in the calyces. To study whether these claims are valid, it is necessary to produce an extract with a high anthocyanin content and to have available a method to identify and quantify the individual compounds in the product. A method of extraction and purification has been developed based on a polyamide column chromatographic purification step. Using this method, anthocyanin concentrates were produced containing from 57 to 64% of delphinidin-3- sambubioside plus cyanidin-3-sambubioside. A rapid, efficient and validated HPLC analytical method was developed and used for the analysis of the anthocyanin concentrate.


Asunto(s)
Antocianinas/análisis , Flores/química , Hibiscus/química , Cromatografía Líquida de Alta Presión , Disacáridos/análisis , Extractos Vegetales/química , Estándares de Referencia , Reproducibilidad de los Resultados , Espectrofotometría Ultravioleta
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA